Should I stay or should I go? A qualitative study exploring participation in a urology clinical trial.


Journal

International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 16 07 2018
accepted: 28 09 2018
pubmed: 18 10 2018
medline: 14 8 2019
entrez: 18 10 2018
Statut: ppublish

Résumé

The aim of this study was to identify modifiable factors to improve recruitment in a urology clinical trial of women with recurrent urinary tract infection (rUTI). An embedded qualitative study was conducted with patients and recruiting clinicians in the first 8 months of the trial. We present a matrix of factors influencing how patients make decisions about trial participation. This was a qualitative study using telephone interviews. When they were first approached about the trial, women were asked to complete an expression of interest form if they wished to be contacted for an interview. Data were analysed thematically. NVivo 10 software (Qualitative data analysis software. 10th ed: QSR International Pty Ltd; 2012) was used as a management tool. Thirty patients and 11 clinicians were interviewed. Influences on patient participation included the impact of rUTI on quality of life (QoL), understanding of antibiotic resistance, and previous experiences with antibiotics either positive or negative. Very few women who declined the trial agreed to be interviewed. However, some of those who participated had reservations about it. These included the perceived risk of trying a new treatment, trial length, and the burden of participating. One person interviewed left the trial because of repeated infections and difficulties getting general practitioner appointments. A combination of factors worked to influence women to decide to participate, to remain in, or to leave the trial. A better understanding of how these factors interact and work can assist in the recruitment and retention of individual trial participants.

Identifiants

pubmed: 30328486
doi: 10.1007/s00192-018-3784-2
pii: 10.1007/s00192-018-3784-2
pmc: PMC6514084
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents, Urinary 0
Hippurates 0
Methenamine J50OIX95QV
methenamine hippurate M329791L57

Types de publication

Journal Article Multicenter Study Pragmatic Clinical Trial Randomized Controlled Trial

Langues

eng

Pagination

9-16

Subventions

Organisme : Department of Health
ID : 13/88/21
Pays : United Kingdom
Organisme : Department of Health
ID : HTA/13/88/21
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : 13/88/21

Références

BMJ. 2002 Oct 5;325(7367):766-70
pubmed: 12364308
Soc Sci Med. 2005 Aug;61(3):685-95
pubmed: 15899326
Br J Gen Pract. 2008 Feb;58(547):98-101
pubmed: 18307853
PLoS Med. 2010 Nov 09;7(11):e1000368
pubmed: 21085696
BMJ Open. 2012 Jan 06;2(1):e000496
pubmed: 22228729
Soc Sci Med. 2012 Feb;74(4):574-81
pubmed: 22236642
Exp Gerontol. 2012 Apr;47(4):342-5
pubmed: 22310657
Health Expect. 2014 Oct;17(5):670-82
pubmed: 22712887
Int Urogynecol J. 2013 Jun;24(6):969-75
pubmed: 23114890
Trials. 2012 Nov 29;13:228
pubmed: 23190503
J Paediatr Child Health. 2013 Jan;49(1):57-62
pubmed: 23198794
Drug Inf J. 2009 Jul;43(4):null
pubmed: 24311825
BMC Med Res Methodol. 2014 Jan 23;14:10
pubmed: 24456229
J Clin Epidemiol. 2014 Aug;67(8):912-20
pubmed: 24811157
Trials. 2014 Aug 13;15:323
pubmed: 25115160
Trials. 2015 Jan 07;16:3
pubmed: 25566971
Rheumatol Int. 2015 Aug;35(8):1423-30
pubmed: 25636236
Health Res Policy Syst. 2015 Mar 12;13:8
pubmed: 25971302
Clin Trials. 2015 Dec;12(6):646-53
pubmed: 26062594
BMC Pregnancy Childbirth. 2015 Sep 04;15:207
pubmed: 26341516
Ger Med Sci. 2015 Oct 14;13:Doc17
pubmed: 26512232
Trials. 2016 Jun 08;17(1):283
pubmed: 27278130
J Health Commun. 2017 Feb;22(2):95-101
pubmed: 28085636
BMJ Open. 2017 Mar 20;7(3):e015276
pubmed: 28320800

Auteurs

Mabel Leng Sim Lie (MLS)

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
School of Geography, Politics and Sociology, Newcastle University, Newcastle upon Tyne, UK.

Jan Lecouturier (J)

Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK.

Christopher Harding (C)

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. chris.harding@nuth.nhs.uk.
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. chris.harding@nuth.nhs.uk.
Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, NE7 7DN, UK. chris.harding@nuth.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH